Self Renewal and Differentiation in Primary Avian Hematopoietic Cells: An Alternative to Mammalian in Vitro Models?

Author(s):  
H. Beug ◽  
T. Metz ◽  
E. W. Müllner ◽  
M. J. Hayman
Blood ◽  
2010 ◽  
Vol 115 (9) ◽  
pp. 1709-1717 ◽  
Author(s):  
Yan Sun ◽  
Lijian Shao ◽  
Hao Bai ◽  
Zack Z. Wang ◽  
Wen-Shu Wu

Abstract Both extrinsic and intrinsic mechanisms tightly govern hematopoietic stem cell (HSC) decisions of self-renewal and differentiation. However, transcription factors that can selectively regulate HSC self-renewal division after stress remain to be identified. Slug is an evolutionarily conserved zinc-finger transcription factor that is highly expressed in primitive hematopoietic cells and is critical for the radioprotection of these key cells. We studied the effect of Slug in the regulation of HSCs in Slug-deficient mice under normal and stress conditions using serial functional assays. Here, we show that Slug deficiency does not disturb hematopoiesis or alter HSC homeostasis and differentiation in bone marrow but increases the numbers of primitive hematopoietic cells in the extramedullary spleen site. Deletion of Slug enhances HSC repopulating potential but not its homing and differentiation ability. Furthermore, Slug deficiency increases HSC proliferation and repopulating potential in vivo after myelosuppression and accelerates HSC expansion during in vitro culture. Therefore, we propose that Slug is essential for controlling the transition of HSCs from relative quiescence under steady-state condition to rapid proliferation under stress conditions. Our data suggest that inhibition of Slug in HSCs may present a novel strategy for accelerating hematopoietic recovery, thus providing therapeutic benefits for patients after clinical myelosuppressive treatment.


Blood ◽  
2003 ◽  
Vol 102 (13) ◽  
pp. 4369-4376 ◽  
Author(s):  
James C. Mulloy ◽  
Jorg Cammenga ◽  
Francisco J. Berguido ◽  
Kaida Wu ◽  
Ping Zhou ◽  
...  

AbstractHematopoiesis is a complex process involving hematopoietic stem cell (HSC) self-renewal and lineage commitment decisions that must continue throughout life. Establishing a reproducible technique that allows for the long-term ex vivo expansion of human HSCs and maintains self-renewal and multipotential differentiation will allow us to better understand these processes, and we report the ability of the leukemia-associated AML1-ETO fusion protein to establish such a system. AML1-ETO-transduced human CD34+ hematopoietic cells routinely proliferate in liquid culture for more than 7 months, remain cytokine dependent for survival and proliferation, and demonstrate self-renewal of immature cells that retain both lymphoid and myeloid potential in vitro. These cells continue to express the CD34 cell surface marker and have ongoing telomerase activity with maintenance of telomere ends, however they do not cause leukemia in nonobese diabetic-severe combined immunodeficiency (NOD/SCID) mice. Identification of the signaling pathways that are modulated by AML1-ETO and lead to the self-renewal of immature human progenitor cells may assist in identifying compounds that can efficiently expand human stem and progenitor cells ex vivo. (Blood. 2003; 102:4369-4376)


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 493-493
Author(s):  
Ingrid Lintmaer ◽  
Michael A. Weinreich ◽  
C. Anthony Blau

Abstract Fibroblast growth factor receptor-1 (FGFR-1) signaling has been implicated in self renewal and proliferation of hematopoietic stem cells. We have studied the effect of a conditional FGFR-1 in genetically modified primary mouse bone marrow cells. The activity of the conditional FGFR-1 is dependent on the presence of a drug called a chemical inducer of dimerization (CID). For these studies we used a bicistronic vector encoding green fluorescence protein (GFP) as a marker and a fusion protein made up of the intracellular portion of FGFR-1 and the CID binding domain. To test the construct in vitro we plated transduced mouse bone marrow cells in 10% serum with or without the CID, AP20187 (100 nM). While the cells without CID died within two weeks, in the culture with CID the transduced, GFP marked cells proliferated. These hematopoietic cells have proliferated in vitro for over 30 weeks. This makes FGFr-1 only the second CID dependent receptor, other than mpl, that is able to support long-term self renewal of primary hematopoietic cells. By day 28 of culture cells had expanded from 106 to 1.2x1012 cells. The differentiation potential of these cells was tested by transplanting 8 million cells into each of 5 lethally irradiated (1050 cGy) congenic recipients. Four mice are alive 76 days post transplantation, with mean frequencies of GFP positive red cells, platelets, granulocytes, monocytes, B cells and T cells of 55%, 5%, 85%, 98%, 42% and 2%, respectively. These findings indicate that cells expanded under the influence of FGFR-1 signaling retain both lymphoid and myeloid repopulating ability. Additionally, CID-mediated activation of FGFR-1 induced a dramatic rise in genetically modfied red cells, granulocytes and monocytes in vivo. These findings point to a clear difference between CID induced activation of FGFR-1 compared to our previous studies using the thrombopoietin receptor, where effects on neutrophils and monocytes are modest and variable. The CID controlled activation of FGFR-1 may have utility for control of genetically modified hematopoietic cells.


1996 ◽  
Vol 93 (4) ◽  
pp. 1470-1474 ◽  
Author(s):  
A. L. Petzer ◽  
D. E. Hogge ◽  
P. M. Landsdorp ◽  
D. S. Reid ◽  
C. J. Eaves

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2476-2476
Author(s):  
Vitalyi Senyuk ◽  
Kavitha Premanand ◽  
Peng Xu ◽  
Francesca Cattaneo ◽  
Jerome Dickstein ◽  
...  

Abstract Abstract 2476 The inappropriate expression of EVI1 is associated with aggressive myelodysplastic syndromes (MDS) and acute myeloid leukemia. We previously showed that in vivo EVI1 causes an MDS-like disease in mice and that in vitro it alters cell cycling, self-renewal, and differentiation pathways of primary bone marrow (BM) cells. It is likely that these alterations contribute to the oncogenic potential of EVI1. MicroRNAs (miRNA) are small noncoding RNAs that are 21 to 25 nt in length that up- and down-regulate gene expression during cell development, proliferation, differentiation, and apoptosis. MiRNAs play a critical role in solid and hematopoietic cancers. We found that in hematopoietic cells the expression of several miRNAs is significantly altered by EVI1. Among them, miRNA-124 is strongly downregulated in EVI1-expressing primary BM and 32Dcl3 cells. To evaluate the role of miRNA-124 in primary murine BM cells, we isolated Lin- cells and infected the cells with the empty vector, EVI1, or both EVI1 and miRNA-124. We confirmed that EVI1 alters cellular pathways regulating self-renewal, S1 phase entry, and differentiation. More importantly, however, we found that when miRNA-124 is co-expressed with EVI1, the expression of proteins such as Cyclin D3 and BMI-1, that control some of these pathways, is normalized. These results suggest that the effects of EVI1 are mediated by miRNA-124 repression. We hypothesized that the down-regulation of miRNA-124 could be associated with inappropriate DNA methylation of the miRNA. Both in man and mouse, there are three known alleles of miRNA-124. In the mouse, the alleles are located on chromosome bands 2H4, 3A1, and 14D1. Analysis of the three alleles indicates that miRNA-124-3 harbors the larger number of CpG dinucleotides, including 24 CpG within a stretch of 190 bp upstream of and overlapping the stem-loop start-site. By using the bisulfite DNA sequencing method, we found that in BM cells the number of methylated CpG dinucleotides in this region is significantly increased after EVI1 expression. The DNA methylation is mostly centered in two clusters, which we named cluster I and cluster II. These data clearly show that miRNA-124 is a critical target of EVI1 in human diseases. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
1999 ◽  
Vol 94 (7) ◽  
pp. 2161-2168 ◽  
Author(s):  
H. Glimm ◽  
C.J. Eaves

Recently, culture conditions that stimulate the proliferation of primitive hematopoietic cells defined by various phenotypic and functional endpoints in vitro have been identified. However, evidence that they support a high probability of self-renewal leading to a large net expansion in vitro of transplantable cells with lympho-myeloid repopulating ability has been more difficult to obtain. The present study was designed to investigate whether the low overall expansion of human repopulating hematopoietic cells seen in vitro reflects a selective unresponsiveness of these rare cells to the growth factors currently used to stimulate them or, alternatively, whether they do proliferate in vitro but lose engrafting potential. For this, we used a high-resolution procedure for tracking and reisolating cells as a function of their proliferation history based on the loss of cellular fluorescence after staining with (5- and 6-) carboxyfluorescein diacetate succinimidyl ester. The results show that the vast majority of long-term culture-initiating cells and in vivo lympho-myeloid competitive repopulating units present in 5-day suspension cultures initiated with CD34+ human cord blood and fetal liver cells are the progeny of cells that have divided at least once in response to stimulation by interleukin-3, interleukin-6, granulocyte colony-stimulating factor, Steel factor, and Flt3-ligand. Thus, most human repopulating cells from these two sources are stimulated to undergo multiple divisions under currently used short-term suspension culture conditions and a proportion of these retain engraftment potential.


Blood ◽  
2007 ◽  
Vol 109 (9) ◽  
pp. 3687-3696 ◽  
Author(s):  
Mattias Magnusson ◽  
Ann C. M. Brun ◽  
Noriko Miyake ◽  
Jonas Larsson ◽  
Mats Ehinger ◽  
...  

Abstract The Homeobox (Hox) transcription factors are important regulators of normal and malignant hematopoiesis because they control proliferation, differentiation, and self-renewal of hematopoietic cells at different levels of the hematopoietic hierarchy. In transgenic mice we show that the expression of HOXA10 is tightly regulated by doxycycline. Intermediate concentrations of HOXA10 induced a 15-fold increase in the repopulating capacity of hematopoietic stem cells (HSCs) after 13 days of in vitro culture. Notably, the proliferation induction of HSC by HOXA10 was dependent on the HOXA10 concentration, because high levels of HOXA10 had no effect on HSC proliferation. Furthermore, high levels of HOXA10 blocked erythroid and megakaryocyte development, demonstrating that tight regulation of HOXA10 is critical for normal development of the erythroid and megakaryocytic lineages. The HOXA10-mediated effects on hematopoietic cells were associated with altered expression of genes that govern stem-cell self-renewal and lineage commitment (eg, hepatic leukemia factor [HlF], Dickkopf-1 [Dkk-1], growth factor independent-1 [Gfi-1], and Gata-1). Interestingly, binding sites for HOXA10 were found in HLF, Dkk-1, and Gata-1, and Dkk-1 and Gfi-1 were transcriptionally activated by HOXA10. These findings reveal novel molecular pathways that act downstream of HOXA10 and identify HOXA10 as a master regulator of postnatal hematopoietic development.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 725-725
Author(s):  
Tomer Itkin ◽  
Chaitanya R Badwe ◽  
Sean Houghton ◽  
Yang Lin ◽  
Ying Liu ◽  
...  

During adulthood and embryogenesis, fate decisions of hematopoietic stem and progenitor cells (HSPCs), such as specification, self-renewal, and differentiation are tightly regulated by their neighboring niche cells. Moreover, distinct types of niches supply differential cues to direct alternative cell fates for HSPCs. Yet, currently the intrinsic mechanisms balancing HSPC response obliqueness to microenvironmental signals are unknown. Friend Leukemia integration-1 (Fli-1), is an ETS transcription factor expressed by vascular beds and hematopoietic lineages. Fli-1 belongs to the "heptad factors" which are hypothesized to specify and sustain a hematopoietic cell fate. While Fli-1 overexpression is linked to leukemia, the functional role Fli-1 plays in HSPC specification and maintenance remains undefined. We show that inducible deletion of Fli-1 using a Rosa-CreERT2 transgenic adult mice (Fli-1ROSAΔ), results in a rapid thrombocytopenia-associated mortality. Transplantation of Fli-1ROSAΔ bone marrow (BM) cells into WT recipients, to exclude vascular-mediated defects, followed by induction of Fli-1 deletion, resulted with the same phenotype. In a set of modulated competitive transplantation experiments (differential induction time points pre- or post-transplant), we observed defective ability of Fli-1ROSAΔ HSPCs to lodge, engraft, and to sustain hematopoiesis post repopulation. Fli-1 deficient HSPCs exhibited reduced quiescent cell cycling status, a hallmark of stemness, and displayed enhanced apoptosis. Thus, Fli-1 is essential for previously unrecognized cell-autonomous HSPC functions. To determine whether Fli-1 modulates HSPC specification, Fli-1 was conditionally deleted using a developmental VE-cadherin (CDH5)-Cre transgenic model (Fli-1CDH5Δ). This resulted with premature mortality of Fli-1CDH5Δ embryos, accompanied with a hemorrhagic phenotype. Reduced numbers of hematopoietic cells were still detected in the AGM of e10.5 Fli-1CDH5Δ embryos. Conditional Fli-1 deletion using a developmental hematopoietic Vav-1 Cre transgenic model (Fli-1Vav-1Δ) resulted again with premature mortality. Reduced presence of embryonic Fli-1Vav-1Δ liver HSPCs was observed at e12.5. We also applied two in vitro co-culture systems, to study Fli-1 in endothelial to hematopoietic transition (EHT). First, isolated hemogenic endothelial cells (HEC) from WT and Fli-1ROSAΔ embryos were co-cultured with AGM-derived vascular niche. HECs isolated from Fli-1ROSAΔ AGM were still able to convert to CD45+ cells, however these cells did not expand on a vascular niche. Secondly, we have applied an endothelial to hematopoietic reprogramming system in which isolated lung ECs are virally introduced with DOX inducible FosB, Gfi1, Runx1, and Spi1 (FGRS) factors and co-cultured with vascular niche cells. Both WT and Fli-1ROSAΔ ECs were able to acquire a hemogenic like state resulting with a final capacity to convert into hematopoietic cells. Again, Fli-1ROSAΔ cells displayed lesser numbers of CD45+ cells at the end point, presumably due to impaired interaction with the vascular niche. Indeed, reduced expansion capacity was observed both for mature CD45+ and for HSPC derived from Fli-1CDH5Δ AGM region. Adult Fli-1ROSAΔ HSPCs exhibited the same niche-dependent expansion defect. Induction of Fli-1 deletion in vitro in adult HSPCs revealed loss of dependency on vascular niche inductive signals, as no additive expansion effect was observed for Fli-1ROSAΔ HSPCs in the presence of a vascular niche. Hence, Fli-1 is essential for HSPC expansion rather than hematopoietic specification. Differential RNA-seq analysis combined with epigenetic studies of expanding WT and Fli-1ROSAΔ HSPCs, revealed dysregulation of Fli-1-controlled pathways involved in transduction of microenvironmental signals for self-renewal. Unexpectedly, H3K27Ac analysis, a marker for transcriptional priming, revealed increased global acetylation of Fli-1ROSAΔ HSPCs' chromatin. Therefor, Fli-1 may not only perform as transcription activator, but foremostly as a genomic suppressor via modulation of histone acetylation status. Decrypting the mechanism(s) by which Fli-1 orchestrates HSPC self-renewal, may promote an improved expansion protocol of human HSPC pre-transplantation, and provide additional insights for microenvironmental sensing by Fli-1-dependent leukemic cells. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2623-2623
Author(s):  
Julie M. Fortier ◽  
Jacqueline E. Payton ◽  
Patrick Cahan ◽  
Timothy J. Ley ◽  
Matthew J. Walter ◽  
...  

Abstract Abstract 2623 Poster Board II-599 The t(8;21)(q22;q22) translocation, present in 10–15% of adult acute myeloid leukemia (AML) cases produces the AML1/ETO (AE) fusion protein. The molecular mechanism of AE action is not well understood. Using Affymetrix RNA expression array analysis on RNA isolated from whole bone marrow (BM) aspirates from patients with de novo AML (n=113), we identified POU4F1 as an expression outlier uniquely associated with t(8;21). All t(8;21) positive patients in this cohort (n=4) had POU4F1 expression levels exceeding 2 SD above the mean for this cohort. None of the t(8;21) negative AML samples or normal CD34+ BM samples (n=5) had POU4F1 levels above this threshold. POU4F1 is a POU domain containing transcription factor that has been studied most extensively in neurons of the caudal CNS and peripheral sensory nervous system. Pou4f1 null mice die peripartum from motor neuron failure. Given the strong correlation between POU4F1 expression and t(8;21), we hypothesized that POU4F1 is a direct transcriptional target of AE and a mediator of its activity. We found that transient or stable over-expression of AE in primary mouse BM or human cell lines did not increase the levels of POU4F1 when analyzed by qRT-PCR, implying that POU4F1 over-expression in t(8;21) AML is AE independent. AE is known to cause increased self renewal of hematopoietic progenitor cells in vitro. To determine whether Pou4f1 may contribute to this phenotype we retrovirally transduced murine BM cells with AE, Pou4f1, or empty vector. We then performed weekly clonal serial replating of myeloid progenitors in cytokine enriched methocellulose media. Progenitors transduced with AE had robust replating activity (15–20/24 CFUs replated for at least five generations in three independent experiments), whereas cells transduced with Pou4f1 did not (1-4/24 CFUs replated; P <0.05). We next used Pou4f1 null mice to determine whether Pou4f1 is required for AE induced progenitor self renewal. We repeated the serial replating assay using Pou4f1 +/+, +/−, or −/− E14.5-16.5 fetal liver cells (3 independent experiments, n=3 mice per genotype). Regardless of Pou4f1 genotype, cells transduced with AE retained replating capacity for five generations. Taken together these results indicate Pou4f1 is neither necessary nor sufficient for enhanced self renewal of hematopoietic progenitors in vitro. To further elucidate the role of POU4F1 in t(8;21) AML, we investigated what effect Pou4f1 had on the transcriptional profile of hematopoietic cells. Pou4f1 +/+ or −/− fetal liver cells were retrovirally transduced to produce cells with high (MSCV-IRES-Pou4f1-GFP in +/+), normal (MSCV-IRES-GFP in +/+), or no (MSCV-IRES-GFP in −/−) Pou4f1 expression. GFP positive cells were sorted and RNA was prepared. Affymetrix MOE430v2.0 GeneChip microarrays were run and comparisons were made between the gene expression profiles of the three experimental groups (each group n=3). As expected, since Pou4f1 is not normally expressed in hematopoietic cells, the gene expression profiles between Pou4f1 wildtype and null cells showed no significant differences. Comparisons of the cells expressing high levels of Pou4f1 to Pou4f1 wildtype or null, however, revealed 114 differentially expressed genes (FDR<0.25). Using Gene Set Enrichment Analysis on our AML data, we found that the human homologs of these 114 genes were significantly enriched in t(8;21) positive compared to t(8;21) negative patients (FDR q value = 0.018), implying that the Pou4f1 gene expression signature is conserved from mice to humans and is retained throughout leukemic transformation. Remarkably, unsupervised clustering performed on the expression profiles of the 114 Pou4f1 signature genes alone was sufficient to separately group the t(8;21) patients from all the other AML patients. Of these 114 genes, the expression of eight (PPAPDC1B, PELI2, FAM69B, ROBO1, SOX4, CAV1, H2AFV, PLXDC2) was significantly increased (P<0.01 by t-test) up to 33-fold (CAV1) in t(8;21) positive vs. negative patients. In this cross species analysis we identified a POU4F1 gene expression signature that distinguishes between t(8;21) positive and negative AML samples. These surprising results directly refute the assumption that the gene expression profile of t(8;21) AML is solely attributable to AE and suggest that POU4F1 is an important independent contributor to the pathophysiology of these leukemias. Disclosures: No relevant conflicts of interest to declare.


2014 ◽  
Vol 226 (06) ◽  
Author(s):  
D William ◽  
M Linnebacher ◽  
CF Classen

Sign in / Sign up

Export Citation Format

Share Document